Screening for Syphilis Infection in Nonpregnant Adolescents and Adults: US Preventive Services Task Force Reaffirmation Recommendation Statement.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
27 09 2022
Historique:
entrez: 27 9 2022
pubmed: 28 9 2022
medline: 30 9 2022
Statut: ppublish

Résumé

Syphilis is a sexually transmitted infection that can progress through different stages (primary, secondary, latent, and tertiary) and cause serious health problems if left untreated. Reported cases of primary and secondary syphilis in the US increased from a record low of 2.1 cases per 100 000 population in 2000 and 2001 to 11.9 cases per 100 000 population in 2019. Men account for the majority of cases (83% of primary and secondary syphilis cases in 2019), and rates among women nearly tripled from 2015 to 2019. To reaffirm its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a reaffirmation evidence update focusing on targeted key questions evaluating the performance of risk assessment tools and the benefits and harms of screening for syphilis in nonpregnant adolescents and adults. Asymptomatic, nonpregnant adolescents and adults who have ever been sexually active and are at increased risk for syphilis infection. Using a reaffirmation process, the USPSTF concludes with high certainty that there is a substantial net benefit of screening for syphilis infection in nonpregnant persons who are at increased risk for infection. The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection. (A recommendation).

Identifiants

pubmed: 36166020
pii: 2796685
doi: 10.1001/jama.2022.15322
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

1243-1249

Commentaires et corrections

Type : SummaryForPatientsIn
Type : CommentIn
Type : CommentIn

Auteurs

Carol M Mangione (CM)

University of California, Los Angeles.

Michael J Barry (MJ)

Harvard Medical School, Boston, Massachusetts.

Wanda K Nicholson (WK)

University of North Carolina at Chapel Hill.

Michael Cabana (M)

Albert Einstein College of Medicine, New York, New York.

David Chelmow (D)

Virginia Commonwealth University, Richmond.

Tumaini Rucker Coker (TR)

University of Washington, Seattle.

Esa M Davis (EM)

University of Pittsburgh, Pittsburgh, Pennsylvania.

Katrina E Donahue (KE)

University of North Carolina at Chapel Hill.

Carlos Roberto Jaén (CR)

The University of Texas Health Science Center, San Antonio.

Martha Kubik (M)

George Mason University, Fairfax, Virginia.

Li Li (L)

University of Virginia, Charlottesville.

Gbenga Ogedegbe (G)

New York University, New York, New York.

Lori Pbert (L)

University of Massachusetts Medical School, Worcester.

John M Ruiz (JM)

University of Arizona, Tucson.

James Stevermer (J)

University of Missouri, Columbia.

John B Wong (JB)

Tufts University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH